Dasatinib
Prostate Carcinoma
National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 81/ 100
Competitive context
114 Active assets in the Prostate Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
Enzalutamide Pfizer | Phase 4 | BBB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BBB |
Degarelix Baptist Health South Florida | Phase 3 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →